Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 7/2017

18.01.2017 | Original Article

Acinetobacter baumannii bacteraemia in patients with haematological malignancy: a multicentre retrospective study from the Infection Working Party of Jiangsu Society of Hematology

verfasst von: X. Wang, L. Zhang, A. Sun, X. Yang, W. Sang, Y. Jiang, J. Cheng, J. Wang, M. Zhou, B. Chen, J. Ouyang

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

Acinetobacter baumannii (Ab) bacteraemia in patients with haematological malignancies is fatal but rarely reported. We explored the clinical characteristics, drug resistances and prognostic factors in these patients. This multicentre, retrospective study was conducted at the department of haematology wards of 18 tertiary hospitals in China from January 2014 to June 2015. The total clinical isolates from every source were collected from patients with haematological malignancy. Haematological malignancy patients diagnosed with Ab bacteraemia were analysed. During the study period, 40 patients with Ab bacteraemia were identified, accounting for 2.9% (40/1358) of bacteraemia cases, of which 25 (62.5%) had acute leukaemia (AL) and 27 (67.5%) had neutropaenia. Compared with non-neutropaenic patients, neutropaenic patients showed higher Acute Physiology and Chronic Health Evaluation (APACHE) scores and 30-day mortality rates (p < 0.05). The in vitro antibiotic susceptibility of Ab to colistin was highest, at 100%, followed by that of tigecycline (91.30%) and amikacin (75.86%). Compared with the patients who had carbapenem-susceptible Ab infections, patients infected with carbapenem-resistant Ab (CRAB) had significantly longer hospital stays and were more likely to have had exposure to carbapenem before bacteraemia (p < 0.05). The 30-day mortality rate was 32.5%. CRAB, neutropaenia, higher APACHE score, Pitt bacteraemia score and inappropriate initial antimicrobial therapy were significantly associated with 30-day mortality. Multivariable analysis showed that APACHE score and CRAB were independent predictors of 30-day mortality. Haematologic patients with AL and febrile neutropaenia were at high risk of Ab bacteraemia. More attention should be paid to CRAB, which is an independent risk factor for mortality in haematological malignancy patients with Ab bacteraemia.
Literatur
1.
Zurück zum Zitat Chen CH, Lin LC, Chang YJ, Huang CC, Liu CE, Young TG (2003) Analysis of prognostic factors in 95 patients with Acinetobacter baumannii bacteremia. Infection 31:331–335. doi:10.1007/s15010-003-3223-1 PubMed Chen CH, Lin LC, Chang YJ, Huang CC, Liu CE, Young TG (2003) Analysis of prognostic factors in 95 patients with Acinetobacter baumannii bacteremia. Infection 31:331–335. doi:10.​1007/​s15010-003-3223-1 PubMed
3.
Zurück zum Zitat Freire MP, de Oliveira Garcia D, Garcia CP, Campagnari Bueno MF, Camargo CH, Kono Magri AS, Francisco GR, Reghini R, Vieira MF, Ibrahim KY, Rossi F, Hajjar L, Levin AS, Hoff PM, Pierrotti LC, Abdala E (2016) Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia. Clin Microbiol Infect 22:352–358. doi:10.1016/j.cmi.2015.12.010 CrossRefPubMed Freire MP, de Oliveira Garcia D, Garcia CP, Campagnari Bueno MF, Camargo CH, Kono Magri AS, Francisco GR, Reghini R, Vieira MF, Ibrahim KY, Rossi F, Hajjar L, Levin AS, Hoff PM, Pierrotti LC, Abdala E (2016) Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia. Clin Microbiol Infect 22:352–358. doi:10.​1016/​j.​cmi.​2015.​12.​010 CrossRefPubMed
4.
Zurück zum Zitat Lahmer T, Messer M, Schnappauf C, Schmidt A, Schmid RM, Huber W (2014) Acinetobacter baumannii sepsis is fatal in medical intensive care unit patients: six cases and review of literature. Anaesth Intensive Care 42:666–668PubMed Lahmer T, Messer M, Schnappauf C, Schmidt A, Schmid RM, Huber W (2014) Acinetobacter baumannii sepsis is fatal in medical intensive care unit patients: six cases and review of literature. Anaesth Intensive Care 42:666–668PubMed
5.
Zurück zum Zitat Routsi C, Pratikaki M, Platsouka E, Sotiropoulou C, Nanas S, Markaki V, Vrettou C, Paniara O, Giamarellou H, Roussos C (2010) Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. Infection 38:173–180. doi:10.1007/s15010-010-0008-1 CrossRefPubMed Routsi C, Pratikaki M, Platsouka E, Sotiropoulou C, Nanas S, Markaki V, Vrettou C, Paniara O, Giamarellou H, Roussos C (2010) Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. Infection 38:173–180. doi:10.​1007/​s15010-010-0008-1 CrossRefPubMed
7.
Zurück zum Zitat Ñamendys-Silva SA, Correa-García P, García-Guillén FJ, González-Herrera MO, Pérez-Alonso A, Texcocano-Becerra J, Herrera-Gómez A, Cornejo-Juárez P, Meneses-García A (2015) Outcomes of critically ill cancer patients with Acinetobacter baumannii infection. World J Crit Care Med 4:258–264PubMedPubMedCentral Ñamendys-Silva SA, Correa-García P, García-Guillén FJ, González-Herrera MO, Pérez-Alonso A, Texcocano-Becerra J, Herrera-Gómez A, Cornejo-Juárez P, Meneses-García A (2015) Outcomes of critically ill cancer patients with Acinetobacter baumannii infection. World J Crit Care Med 4:258–264PubMedPubMedCentral
8.
Zurück zum Zitat Grupper M, Sprecher H, Mashiach T, Finkelstein R (2007) Attributable mortality of nosocomial Acinetobacter bacteremia. Infect Control Hosp Epidemiol 28:293–298. doi:10.1086/512629 CrossRefPubMed Grupper M, Sprecher H, Mashiach T, Finkelstein R (2007) Attributable mortality of nosocomial Acinetobacter bacteremia. Infect Control Hosp Epidemiol 28:293–298. doi:10.​1086/​512629 CrossRefPubMed
9.
Zurück zum Zitat Robenshtok E, Paul M, Leibovici L, Fraser A, Pitlik S, Ostfeld I, Samra Z, Perez S, Lev B, Weinberger M (2006) The significance of Acinetobacter baumannii bacteraemia compared with Klebsiella pneumoniae bacteraemia: risk factors and outcomes. J Hosp Infect 64:282–287. doi:10.1016/j.jhin.2006.06.025 CrossRefPubMed Robenshtok E, Paul M, Leibovici L, Fraser A, Pitlik S, Ostfeld I, Samra Z, Perez S, Lev B, Weinberger M (2006) The significance of Acinetobacter baumannii bacteraemia compared with Klebsiella pneumoniae bacteraemia: risk factors and outcomes. J Hosp Infect 64:282–287. doi:10.​1016/​j.​jhin.​2006.​06.​025 CrossRefPubMed
11.
Zurück zum Zitat Al-Anazi KA, Abdalhamid B, Alshibani Z, Awad K, Alzayed A, Hassan H, Alsayiegh M (2012) Acinetobacter baumannii septicemia in a recipient of an allogeneic hematopoietic stem cell transplantation. Case Rep Transplant 2012:646195PubMedPubMedCentral Al-Anazi KA, Abdalhamid B, Alshibani Z, Awad K, Alzayed A, Hassan H, Alsayiegh M (2012) Acinetobacter baumannii septicemia in a recipient of an allogeneic hematopoietic stem cell transplantation. Case Rep Transplant 2012:646195PubMedPubMedCentral
13.
Zurück zum Zitat Gedik H, Simşek F, Kantürk A, Yildirmak T, Arica D, Aydin D, Demirel N, Yokuş O (2014) Bloodstream infections in patients with hematological malignancies: which is more fatal—cancer or resistant pathogens? Ther Clin Risk Manag 10:743–752. doi:10.2147/TCRM.S68450 CrossRefPubMedPubMedCentral Gedik H, Simşek F, Kantürk A, Yildirmak T, Arica D, Aydin D, Demirel N, Yokuş O (2014) Bloodstream infections in patients with hematological malignancies: which is more fatal—cancer or resistant pathogens? Ther Clin Risk Manag 10:743–752. doi:10.​2147/​TCRM.​S68450 CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Lakshmana Gowda K, Marie MA, Al-Sheikh YA, John J, Gopalkrishnan S, Chikkabidare Shashidhar P, Dabwan KH (2014) A 6-year surveillance of antimicrobial resistance patterns of Acinetobacter baumannii bacteremia isolates from a tertiary care hospital in Saudi Arabia during 2005–2010. Libyan J Med 9:24039CrossRefPubMed Lakshmana Gowda K, Marie MA, Al-Sheikh YA, John J, Gopalkrishnan S, Chikkabidare Shashidhar P, Dabwan KH (2014) A 6-year surveillance of antimicrobial resistance patterns of Acinetobacter baumannii bacteremia isolates from a tertiary care hospital in Saudi Arabia during 2005–2010. Libyan J Med 9:24039CrossRefPubMed
18.
Zurück zum Zitat Nazer LH, Kharabsheh A, Rimawi D, Mubarak S, Hawari F (2015) Characteristics and outcomes of Acinetobacter baumannii infections in critically ill patients with cancer: a Matched Case–control Study. Microb Drug Resist 21:556–561. doi:10.1089/mdr.2015.0032 CrossRefPubMed Nazer LH, Kharabsheh A, Rimawi D, Mubarak S, Hawari F (2015) Characteristics and outcomes of Acinetobacter baumannii infections in critically ill patients with cancer: a Matched Case–control Study. Microb Drug Resist 21:556–561. doi:10.​1089/​mdr.​2015.​0032 CrossRefPubMed
19.
20.
Zurück zum Zitat Li P, Niu W, Li H, Lei H, Liu W, Zhao X, Guo L, Zou D, Yuan X, Liu H, Yuan J, Bai C (2015) Rapid detection of Acinetobacter baumannii and molecular epidemiology of carbapenem-resistant A. baumannii in two comprehensive hospitals of Beijing, China. Front Microbiol 6:997. doi:10.3389/fmicb.2015.00997 PubMedPubMedCentral Li P, Niu W, Li H, Lei H, Liu W, Zhao X, Guo L, Zou D, Yuan X, Liu H, Yuan J, Bai C (2015) Rapid detection of Acinetobacter baumannii and molecular epidemiology of carbapenem-resistant A. baumannii in two comprehensive hospitals of Beijing, China. Front Microbiol 6:997. doi:10.​3389/​fmicb.​2015.​00997 PubMedPubMedCentral
21.
Zurück zum Zitat Huang ST, Chiang MC, Kuo SC, Lee YT, Chiang TH, Yang SP, Ti-Yin Y, Chen TL, Fung CP (2012) Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect 45:356–362CrossRefPubMed Huang ST, Chiang MC, Kuo SC, Lee YT, Chiang TH, Yang SP, Ti-Yin Y, Chen TL, Fung CP (2012) Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect 45:356–362CrossRefPubMed
22.
Zurück zum Zitat Kumar A, Randhawa VS, Nirupam N, Rai Y, Saili A (2014) Risk factors for carbapenem-resistant Acinetobacter baumanii blood stream infections in a neonatal intensive care unit, Delhi, India. J Infect Dev Ctries 8:1049–1054. doi:10.3855/jidc.4248 PubMed Kumar A, Randhawa VS, Nirupam N, Rai Y, Saili A (2014) Risk factors for carbapenem-resistant Acinetobacter baumanii blood stream infections in a neonatal intensive care unit, Delhi, India. J Infect Dev Ctries 8:1049–1054. doi:10.​3855/​jidc.​4248 PubMed
23.
Zurück zum Zitat Henig O, Weber G, Hoshen MB, Paul M, German L, Neuberger A, Gluzman I, Berlin A, Shapira C, Balicer RD (2015) Risk factors for and impact of carbapenem-resistant Acinetobacter baumannii colonization and infection: matched case–control study. Eur J Clin Microbiol Infect Dis 34:2063–2068. doi:10.1007/s10096-015-2452-4 CrossRefPubMed Henig O, Weber G, Hoshen MB, Paul M, German L, Neuberger A, Gluzman I, Berlin A, Shapira C, Balicer RD (2015) Risk factors for and impact of carbapenem-resistant Acinetobacter baumannii colonization and infection: matched case–control study. Eur J Clin Microbiol Infect Dis 34:2063–2068. doi:10.​1007/​s10096-015-2452-4 CrossRefPubMed
25.
Zurück zum Zitat Zusman O, Altunin S, Koppel F, Dishon Benattar Y, Gedik H, Paul M (2017) Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother 72:29–39. doi:10.1093/jac/dkw377 CrossRefPubMed Zusman O, Altunin S, Koppel F, Dishon Benattar Y, Gedik H, Paul M (2017) Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother 72:29–39. doi:10.​1093/​jac/​dkw377 CrossRefPubMed
26.
Zurück zum Zitat Karaoglan I, Zer Y, Bosnak VK, Mete AO, Namiduru M (2013) In vitro synergistic activity of colistin with tigecycline or beta-lactam antibiotic/beta-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii. J Int Med Res 41:1830–1837. doi:10.1177/0300060513496172 CrossRefPubMed Karaoglan I, Zer Y, Bosnak VK, Mete AO, Namiduru M (2013) In vitro synergistic activity of colistin with tigecycline or beta-lactam antibiotic/beta-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii. J Int Med Res 41:1830–1837. doi:10.​1177/​0300060513496172​ CrossRefPubMed
27.
Zurück zum Zitat Cikman A, Gulhan B, Aydin M, Ceylan MR, Parlak M, Karakecili F, Karagoz A (2015) In vitro activity of colistin in combination with tigecycline against carbapenem-resistant Acinetobacter baumannii strains isolated from patients with ventilator-associated pneumonia. Int J Med Sci 12:695–700. doi:10.7150/ijms.11988 CrossRefPubMedPubMedCentral Cikman A, Gulhan B, Aydin M, Ceylan MR, Parlak M, Karakecili F, Karagoz A (2015) In vitro activity of colistin in combination with tigecycline against carbapenem-resistant Acinetobacter baumannii strains isolated from patients with ventilator-associated pneumonia. Int J Med Sci 12:695–700. doi:10.​7150/​ijms.​11988 CrossRefPubMedPubMedCentral
28.
29.
Zurück zum Zitat Chen HP, Chen TL, Lai CH, Fung CP, Wong WW, Yu KW, Liu CY (2005) Predictors of mortality in Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect 38:127–136PubMed Chen HP, Chen TL, Lai CH, Fung CP, Wong WW, Yu KW, Liu CY (2005) Predictors of mortality in Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect 38:127–136PubMed
30.
Zurück zum Zitat Joung MK, Kwon KT, Kang CI, Cheong HS, Rhee JY, Jung DS, Chung SM, Lee JA, Moon SY, Ko KS, Chung DR, Lee NY, Song JH, Peck KR (2010) Impact of inappropriate antimicrobial therapy on outcome in patients with hospital-acquired pneumonia caused by Acinetobacter baumannii. J Infect 61:212–218. doi:10.1016/j.jinf.2010.06.014 CrossRefPubMed Joung MK, Kwon KT, Kang CI, Cheong HS, Rhee JY, Jung DS, Chung SM, Lee JA, Moon SY, Ko KS, Chung DR, Lee NY, Song JH, Peck KR (2010) Impact of inappropriate antimicrobial therapy on outcome in patients with hospital-acquired pneumonia caused by Acinetobacter baumannii. J Infect 61:212–218. doi:10.​1016/​j.​jinf.​2010.​06.​014 CrossRefPubMed
31.
Zurück zum Zitat Lee YT, Kuo SC, Yang SP, Lin YT, Tseng FC, Chen TL, Fung CP (2012) Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection. Clin Infect Dis 55:209–215. doi:10.1093/cid/cis385 CrossRefPubMed Lee YT, Kuo SC, Yang SP, Lin YT, Tseng FC, Chen TL, Fung CP (2012) Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection. Clin Infect Dis 55:209–215. doi:10.​1093/​cid/​cis385 CrossRefPubMed
32.
33.
Zurück zum Zitat Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39:309–317. doi:10.1086/421946 CrossRefPubMed Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39:309–317. doi:10.​1086/​421946 CrossRefPubMed
Metadaten
Titel
Acinetobacter baumannii bacteraemia in patients with haematological malignancy: a multicentre retrospective study from the Infection Working Party of Jiangsu Society of Hematology
verfasst von
X. Wang
L. Zhang
A. Sun
X. Yang
W. Sang
Y. Jiang
J. Cheng
J. Wang
M. Zhou
B. Chen
J. Ouyang
Publikationsdatum
18.01.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 7/2017
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-016-2895-2

Weitere Artikel der Ausgabe 7/2017

European Journal of Clinical Microbiology & Infectious Diseases 7/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.